142
Participants
Start Date
March 28, 2014
Primary Completion Date
May 2, 2018
Study Completion Date
August 29, 2019
Abemaciclib
Administered orally
Pemetrexed
Administered IV
Gemcitabine
Administered IV
Ramucirumab
Administered IV
LY3023414
Administered orally
Pembrolizumab
Administered IV
Hospital Universitario Ramon y Cajal, Madrid
Carolinas Medical Center, Charlotte
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Majadahonda
The West Clinic, Germantown
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville
Indiana Cancer Pavilion, Indianapolis
Highlands Oncology Group, Fayetteville
University of New Mexico Cancer Center, Albuquerque
UCLA Department of Medicine-Hematology/Oncology, Los Angeles
University of California, Davis - Health Systems, Sacramento
Hackensack University Medical Center, Hackensack
Merck Sharp & Dohme LLC
INDUSTRY
Eli Lilly and Company
INDUSTRY